Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O00755

UPID:
WNT7A_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
O00755; Q96H90; Q9Y560

BACKGROUND:
The Protein Wnt-7a, integral to the canonical Wnt/beta-catenin signaling, is crucial for dorsal versus ventral patterning during limb development, skeleton development, and urogenital tract development. It also plays roles in CNS angiogenesis, blood-brain barrier regulation, and neural stem cell dynamics, including proliferation, self-renewal, and differentiation.

THERAPEUTIC SIGNIFICANCE:
Protein Wnt-7a's association with diseases such as Limb pelvis hypoplasia aplasia syndrome and Fuhrmann syndrome underscores its therapeutic potential. Targeting Protein Wnt-7a could lead to innovative treatments for these genetic disorders, leveraging its critical role in embryonic development and disease pathogenesis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.